β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6:S580–S590
D’Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R (2008) Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 14:291–301
Benner JS, Nichol MB, Rovner ES et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276–1282
Wein AJ, Andersson KE (2007) Pharmacologic management of storage and emptying failure. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh Urology, 9th edn. Saunders Elsevier, Philadelphia, pp 2093–2094
Igawa Y, Yamazaki Y, Takeda H et al (1999) Functional and molecular biological evidence. Br J Pharmacol 126:819–825
Takeda M, Obara K (1999) Evidence for beta3-adrenoreceptor subtypes. J Pharmacol Exp Ther 288:1367–1373
Fujimura T, Tamura K (1999) Expression and possible functional role of beta3- adrenoceptor in human and rat detrusor muscle. J Urol 161:680–685
Woods M, Carson N (2001) Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 166:1142–1147
Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647
Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C (2012) Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 110(2 Pt 2):E132–E142. doi: 10.1111/j.1464-410X.2012.11240.x
Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318–323
Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817–820
Astellas, Betanis (mirabegron) package insert version 3, March 2012. PMDA. http://www.info.pmda.go.jp/downfiles/ph/PDF/80126_2590014F1021_1_02.pdf . Accessed 10 Aug 2012